Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,148.42
(
0.00%
)
News Focus
News Focus
Post# of 57939
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

gfp927z

Send PM Follow Ignore
Followers 98
Posts 38938
Boards Moderated 89
Alias Born 03/22/2005

gfp927z

Re: neuroinv post# 19910

Thursday, 08/14/2008 3:50:54 PM

Thursday, August 14, 2008 3:50:54 PM

Post# of 57939
Neuro, Here's a theoretical question - let's say RD-1 had finished all dosing prior to when the DSMB discovered the problems in RD-2. Could they then decide to just add more subjects to RD-1, even though the trial was technically over? Are there any clinical trial regulations that would prevent them from doing that, I wonder? Thanks.




















Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today